EMB 07
Alternative Names: EMB-07Latest Information Update: 20 Jun 2024
At a glance
- Originator EpimAb Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Haematological malignancies
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and adverse event data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 01 Mar 2023 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in China (IV) (NCT05607498)
- 28 Feb 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Australia (IV) (NCT05607498)